mRCC: Are we doing all we can to manage adverse events?

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 11 Feb 2015
Views: 4840
Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Prof Bernard Escudier (Institut Gustave-Roussy, Paris, France), Dr Nizar Tannir (University of Texas M.D. Anderson Cancer Center, Houston, USA), and Dr David Cella (Northwestern University, Chicago, USA) discuss the efficacy, tolerability and quality of life issues surrounding metastatic renal cell carcinoma (mRCC) at ESMO 2014 in Madrid.

From the same symposium:

Welcome and introduction

Achieving efficacy beyond clinical trials

Understanding the patient's perspective

Panel discussion

Closing remarks

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.